Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
BidaskClub Downgrades Denali Therapeutics (NASDAQ:DNLI) to Sell
06:54am, Sunday, 01'st Mar 2020
BidaskClub downgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a sell rating in a report released on Wednesday, BidAskClub reports. DNLI has been the subject of a number of ot
Denali Therapeutics Inc. Just Reported And Analysts Have Been Cutting Their Estimates
01:47pm, Saturday, 29'th Feb 2020
It's been a mediocre week for Denali Therapeutics Inc. (NASDAQ:DNLI) shareholders, with the stock dropping 19% to...
Denali Therapeutics Inc. Just Reported And Analysts Have Been Cutting Their Estimates
01:40pm, Saturday, 29'th Feb 2020
There's been a notable change in appetite for Denali Therapeutics Inc. (NASDAQ:DNLI) shares in the week since its...
First Allied Advisory Services Inc. Buys 3,000 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
12:10pm, Saturday, 29'th Feb 2020
First Allied Advisory Services Inc. lifted its stake in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 15.8% in the 4th quarter, Holdings Channel reports. The fund owned 21,950 shares of the compa
Research Analysts Issue Forecasts for Denali Therapeutics Inc's FY2019 Earnings (NASDAQ:DNLI)
08:22am, Saturday, 29'th Feb 2020
Denali Therapeutics Inc (NASDAQ:DNLI) – Equities research analysts at Jefferies Financial Group issued their FY2019 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research
Denali Therapeutics (NASDAQ:DNLI) Upgraded to Buy at ValuEngine
11:46am, Friday, 28'th Feb 2020
Denali Therapeutics (NASDAQ:DNLI) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Wednesday, ValuEngine reports. Several oth
Denali Therapeutics (NASDAQ:DNLI) Shares Down 12.1%
10:44am, Friday, 28'th Feb 2020
Denali Therapeutics Inc (NASDAQ:DNLI)’s share price fell 12.1% on Thursday . The company traded as low as $19.01 and last traded at $19.02, 1,097,060 shares traded hands during trading. An increase
BRIEF-Denali Therapeutics Inc Posts Qtrly Loss Per Share Of $0.56
11:01pm, Thursday, 27'th Feb 2020
Denali Therapeutics Inc:
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue Estimates
10:55pm, Thursday, 27'th Feb 2020
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue Estimates
10:55pm, Thursday, 27'th Feb 2020
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
09:30pm, Thursday, 27'th Feb 2020
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered.
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
09:30pm, Thursday, 27'th Feb 2020
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad...
Denali Therapeutics (DNLI) - Analysts' Weekly Ratings Changes
06:10am, Thursday, 27'th Feb 2020
A number of firms have modified their ratings and price targets on shares of Denali Therapeutics (NASDAQ: DNLI) recently: 2/26/2020 – Denali Therapeutics was downgraded by analysts at BidaskClub fro
Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated at Jefferies Financial Group
09:40am, Wednesday, 26'th Feb 2020
Equities researchers at Jefferies Financial Group began coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a report issued on Monday, Marketbeat reports. The firm set a “buy” rating and a
Denali Therapeutics (NASDAQ:DNLI) Downgraded by BidaskClub to "Sell"
08:16am, Wednesday, 26'th Feb 2020
Denali Therapeutics (NASDAQ:DNLI) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, BidAsk
